156 related articles for article (PubMed ID: 23795919)
1. Characterization of a chemical affinity probe targeting Akt kinases.
Pachl F; Plattner P; Ruprecht B; Médard G; Sewald N; Kuster B
J Proteome Res; 2013 Aug; 12(8):3792-800. PubMed ID: 23795919
[TBL] [Abstract][Full Text] [Related]
2. Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity.
Rhodes N; Heerding DA; Duckett DR; Eberwein DJ; Knick VB; Lansing TJ; McConnell RT; Gilmer TM; Zhang SY; Robell K; Kahana JA; Geske RS; Kleymenova EV; Choudhry AE; Lai Z; Leber JD; Minthorn EA; Strum SL; Wood ER; Huang PS; Copeland RA; Kumar R
Cancer Res; 2008 Apr; 68(7):2366-74. PubMed ID: 18381444
[TBL] [Abstract][Full Text] [Related]
3. New affinity probe targeting VEGF receptors for kinase inhibitor selectivity profiling by chemical proteomics.
Ku X; Heinzlmeir S; Helm D; Médard G; Kuster B
J Proteome Res; 2014 May; 13(5):2445-52. PubMed ID: 24712744
[TBL] [Abstract][Full Text] [Related]
4. Cyclic GMP/protein kinase G type-Iα (PKG-Iα) signaling pathway promotes CREB phosphorylation and maintains higher c-IAP1, livin, survivin, and Mcl-1 expression and the inhibition of PKG-Iα kinase activity synergizes with cisplatin in non-small cell lung cancer cells.
Wong JC; Bathina M; Fiscus RR
J Cell Biochem; 2012 Nov; 113(11):3587-98. PubMed ID: 22740515
[TBL] [Abstract][Full Text] [Related]
5. Computational proteomics of biomolecular interactions in the sequence and structure space of the tyrosine kinome: deciphering the molecular basis of the kinase inhibitors selectivity.
Verkhivker GM
Proteins; 2007 Mar; 66(4):912-29. PubMed ID: 17173284
[TBL] [Abstract][Full Text] [Related]
6. Aminofurazans as potent inhibitors of AKT kinase.
Rouse MB; Seefeld MA; Leber JD; McNulty KC; Sun L; Miller WH; Zhang S; Minthorn EA; Concha NO; Choudhry AE; Schaber MD; Heerding DA
Bioorg Med Chem Lett; 2009 Mar; 19(5):1508-11. PubMed ID: 19179070
[TBL] [Abstract][Full Text] [Related]
7. Causal reasoning identifies mechanisms of sensitivity for a novel AKT kinase inhibitor, GSK690693.
Kumar R; Blakemore SJ; Ellis CE; Petricoin EF; Pratt D; Macoritto M; Matthews AL; Loureiro JJ; Elliston K
BMC Genomics; 2010 Jul; 11():419. PubMed ID: 20604938
[TBL] [Abstract][Full Text] [Related]
8. Identification of 4-(2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-{[(3S)-3-piperidinylmethyl]oxy}-1H-imidazo[4,5-c]pyridin-4-yl)-2-methyl-3-butyn-2-ol (GSK690693), a novel inhibitor of AKT kinase.
Heerding DA; Rhodes N; Leber JD; Clark TJ; Keenan RM; Lafrance LV; Li M; Safonov IG; Takata DT; Venslavsky JW; Yamashita DS; Choudhry AE; Copeland RA; Lai Z; Schaber MD; Tummino PJ; Strum SL; Wood ER; Duckett DR; Eberwein D; Knick VB; Lansing TJ; McConnell RT; Zhang S; Minthorn EA; Concha NO; Warren GL; Kumar R
J Med Chem; 2008 Sep; 51(18):5663-79. PubMed ID: 18800763
[TBL] [Abstract][Full Text] [Related]
9. Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells.
Remsing Rix LL; Rix U; Colinge J; Hantschel O; Bennett KL; Stranzl T; Müller A; Baumgartner C; Valent P; Augustin M; Till JH; Superti-Furga G
Leukemia; 2009 Mar; 23(3):477-85. PubMed ID: 19039322
[TBL] [Abstract][Full Text] [Related]
10. Comparing immobilized kinase inhibitors and covalent ATP probes for proteomic profiling of kinase expression and drug selectivity.
Lemeer S; Zörgiebel C; Ruprecht B; Kohl K; Kuster B
J Proteome Res; 2013 Apr; 12(4):1723-31. PubMed ID: 23495751
[TBL] [Abstract][Full Text] [Related]
11. Inhibitor-based affinity probes for the investigation of JAK signaling pathways.
Höfener M; Pachl F; Kuster B; Sewald N
Proteomics; 2015 Sep; 15(17):3066-74. PubMed ID: 25959371
[TBL] [Abstract][Full Text] [Related]
12. Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway.
Marzec M; Kasprzycka M; Liu X; El-Salem M; Halasa K; Raghunath PN; Bucki R; Wlodarski P; Wasik MA
Oncogene; 2007 Aug; 26(38):5606-14. PubMed ID: 17353907
[TBL] [Abstract][Full Text] [Related]
13. Characterization of the novel broad-spectrum kinase inhibitor CTx-0294885 as an affinity reagent for mass spectrometry-based kinome profiling.
Zhang L; Holmes IP; Hochgräfe F; Walker SR; Ali NA; Humphrey ES; Wu J; de Silva M; Kersten WJ; Connor T; Falk H; Allan L; Street IP; Bentley JD; Pilling PA; Monahan BJ; Peat TS; Daly RJ
J Proteome Res; 2013 Jul; 12(7):3104-16. PubMed ID: 23692254
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and structure-activity relationship of 3,4'-bispyridinylethylenes: discovery of a potent 3-isoquinolinylpyridine inhibitor of protein kinase B (PKB/Akt) for the treatment of cancer.
Li Q; Woods KW; Thomas S; Zhu GD; Packard G; Fisher J; Li T; Gong J; Dinges J; Song X; Abrams J; Luo Y; Johnson EF; Shi Y; Liu X; Klinghofer V; Des Jong R; Oltersdorf T; Stoll VS; Jakob CG; Rosenberg SH; Giranda VL
Bioorg Med Chem Lett; 2006 Apr; 16(7):2000-7. PubMed ID: 16413780
[TBL] [Abstract][Full Text] [Related]
15. Cell-based proteome profiling of potential dasatinib targets by use of affinity-based probes.
Shi H; Zhang CJ; Chen GY; Yao SQ
J Am Chem Soc; 2012 Feb; 134(6):3001-14. PubMed ID: 22242683
[TBL] [Abstract][Full Text] [Related]
16. DC120, a novel and potent inhibitor of AKT kinase, induces tumor cell apoptosis and suppresses tumor growth.
Deng R; Yang F; Chang SH; Tang J; Qin J; Feng GK; Ding K; Zhu XF
Mol Pharmacol; 2012 Aug; 82(2):189-98. PubMed ID: 22553359
[TBL] [Abstract][Full Text] [Related]
17. Discovery of trans-3,4'-bispyridinylethylenes as potent and novel inhibitors of protein kinase B (PKB/Akt) for the treatment of cancer: Synthesis and biological evaluation.
Li Q; Li T; Zhu GD; Gong J; Claibone A; Dalton C; Luo Y; Johnson EF; Shi Y; Liu X; Klinghofer V; Bauch JL; Marsh KC; Bouska JJ; Arries S; De Jong R; Oltersdorf T; Stoll VS; Jakob CG; Rosenberg SH; Giranda VL
Bioorg Med Chem Lett; 2006 Mar; 16(6):1679-85. PubMed ID: 16403626
[TBL] [Abstract][Full Text] [Related]
18. Imidazo[1,2-a]pyrazines as novel PI3K inhibitors.
Martínez González S; Hernández AI; Varela C; Rodríguez-Arístegui S; Alvarez RM; García AB; Lorenzo M; Rivero V; Oyarzabal J; Rabal O; Bischoff JR; Albarrán M; Cebriá A; Alfonso P; Link W; Fominaya J; Pastor J
Bioorg Med Chem Lett; 2012 Mar; 22(5):1874-8. PubMed ID: 22325943
[TBL] [Abstract][Full Text] [Related]
19. Chemoproteomic characterization of protein kinase inhibitors using immobilized ATP.
Duncan JS; Haystead TA; Litchfield DW
Methods Mol Biol; 2012; 795():119-34. PubMed ID: 21960219
[TBL] [Abstract][Full Text] [Related]
20. Tirucallic acids are novel pleckstrin homology domain-dependent Akt inhibitors inducing apoptosis in prostate cancer cells.
Estrada AC; Syrovets T; Pitterle K; Lunov O; Büchele B; Schimana-Pfeifer J; Schmidt T; Morad SA; Simmet T
Mol Pharmacol; 2010 Mar; 77(3):378-87. PubMed ID: 20018812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
